Fluticasone propionate
- Generic Name
- Fluticasone propionate
- Brand Names
- Advair, Airduo, Airduo Respiclick, Aller-flo, Armonair, Beser, Cutivate, Dymista, Flonase, Flovent, Fluticare, Ticanase, Wixela, Xhance
- Drug Type
- Small Molecule
- Chemical Formula
- C25H31F3O5S
- CAS Number
- 80474-14-2
- Unique Ingredient Identifier
- O2GMZ0LF5W
- Background
Fluticasone propionate is a synthetic glucocorticoid. These drugs are available as inhalers, nasal, sprays, and topical treatments for various inflammatory indications. Fluticasone propionate was first approved in 1990.
- Indication
Fluticasone propionate is indicated as an inhaler for the treatment and management of asthma by prophylaxisas well as inflammatory and pruritic dermatoses. Fluticasone propionate nasal spray is indicated for managing allergic and nonallergic rhinitis.
- Associated Conditions
- Allergic Rhinitis (AR), Allergy to Animal Dander, Allergy to Mold, Allergy to Tree Pollen, Asthma, Bacterial Sinusitis, Chronic Bronchitis, Chronic Obstructive Pulmonary Disease (COPD), Chronic Sinusitis, Dermatitis, Emphysema, Eosinophilic Esophagitis, House Dust Mite Allergy, House dust allergy, Itching of the nose, Nasal Congestion, Non-Allergic Rhinitis, Rhinitis, Rhinitis Perennial, Rhinorrhoea, Seasonal Allergic Rhinitis, Sneezing, Moderate, severe Perennial Allergic Rhinitis (PAR), Moderate, severe Seasonal Allergic Rhinitis
- Associated Therapies
- -
A Study To Determine Effects Of Fluticasone Propionate On Sputum Neutrophils After Inhaled Lipopolysaccharide Challenge In Volunteers
- Conditions
- Interventions
- First Posted Date
- 2011-06-02
- Last Posted Date
- 2012-02-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 17
- Registration Number
- NCT01364519
- Locations
- 🇬🇧
Pfizer Investigational Site, London, United Kingdom
Comparison of Asthma-related Outcomes and Costs in Pediatric Subjects That Received Fluticasone Propionate, Budesonide or Montelukast in a Large Managed Care Population
- First Posted Date
- 2011-04-05
- Last Posted Date
- 2017-07-06
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 9906
- Registration Number
- NCT01328964
Targeted Therapy of Bronchiolitis Obliterans Syndrome
- Conditions
- Interventions
- First Posted Date
- 2011-03-03
- Last Posted Date
- 2017-10-04
- Lead Sponsor
- Stephanie Lee
- Target Recruit Count
- 36
- Registration Number
- NCT01307462
- Locations
- 🇺🇸
Stanford University, Stanford, California, United States
🇺🇸Mayo Clinic - Scottsdale, Scottsdale, Arizona, United States
🇺🇸National Cancer Institute Experimental Transplantation & Immunology Branch, Bethesda, Maryland, United States
Real-world Effectiveness and Cost-effectiveness of Qvar Versus FP, a US Study
- Conditions
- Interventions
- First Posted Date
- 2011-02-01
- Last Posted Date
- 2013-08-05
- Lead Sponsor
- Research in Real-Life Ltd
- Target Recruit Count
- 82903
- Registration Number
- NCT01287351
- Locations
- 🇬🇧
Research in Real Life, Cawston, Norfolk, United Kingdom
Effects of Intranasal Corticosteroid and Montelukast On Nasal Allergen Challenges*
- First Posted Date
- 2010-11-15
- Last Posted Date
- 2012-10-10
- Lead Sponsor
- Creighton University
- Target Recruit Count
- 60
- Registration Number
- NCT01240889
- Locations
- 🇺🇸
Creighton University Medical Center, Omaha, Nebraska, United States
Interactive Acute Smooth Muscle Effects of Salmeterol and Fluticasone in the Airway
- Conditions
- Interventions
- First Posted Date
- 2010-11-01
- Last Posted Date
- 2016-06-30
- Lead Sponsor
- University of Miami
- Target Recruit Count
- 14
- Registration Number
- NCT01231230
Effect of an Inhaled Glucocorticosteroid (ICS) on Endothelial Dysfunction in Cigarette Smokers
- First Posted Date
- 2010-10-07
- Last Posted Date
- 2016-06-29
- Lead Sponsor
- University of Miami
- Target Recruit Count
- 32
- Registration Number
- NCT01216735
- Locations
- 🇺🇸
Human Research Laboratory - University of Miami, Miami, Florida, United States
A Study Comparative of Formoterol/Fluticasone Foraseq® and Fluticasone in Asthma Patients
- Conditions
- Interventions
- First Posted Date
- 2010-09-15
- Last Posted Date
- 2015-06-18
- Lead Sponsor
- Eurofarma Laboratorios S.A.
- Target Recruit Count
- 222
- Registration Number
- NCT01202084
- Locations
- 🇧🇷
IMA Brasil - Instituto de Pesquisa Clínica e Medicina Avançada, São Paulo, Brazil
A Comparison of Patients on AVAMYS ® Versus NASONEX (A Trade Mark of Schering Corporation) and FLIXONASE ® on Key Health Outcome Measures
- Conditions
- Interventions
- First Posted Date
- 2010-09-13
- Last Posted Date
- 2017-08-14
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 540
- Registration Number
- NCT01199757
Single Dose Pharmacokinetics of Intranasal Fluticasone Delivered by a Fixed Combination With Azelastine (MP29 02) in Comparison to Two Different Fluticasone Nasal Sprays
- Conditions
- Interventions
- First Posted Date
- 2010-09-03
- Last Posted Date
- 2022-02-07
- Lead Sponsor
- MEDA Pharma GmbH & Co. KG
- Target Recruit Count
- 30
- Registration Number
- NCT01194622
- Locations
- 🇩🇪
ClinPharmCologne, Cologne, NRW, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.